Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

被引:786
作者
Ledergerber, B
Egger, M
Opravil, M
Telenti, A
Hirschel, B
Battegay, M
Vernazza, P
Sudre, P
Flepp, M
Furrer, H
Francioli, P
Weber, R
机构
[1] Univ Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland
[2] Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol, Avon, England
[3] Univ Lausanne, Div Infect Dis, Lausanne, Switzerland
[4] Univ Lausanne, Div Hosp Prevent Med, Lausanne, Switzerland
[5] Univ Geneva, Div Infect Dis, Geneva, Switzerland
[6] Univ Basel, Outpatient Dept Internal Med, Basel, Switzerland
[7] Cantonal Hosp St Gall, Div Internal Med, St Gallen, Switzerland
[8] Univ Bern, Outpatient Dept Internal Med, Bern, Switzerland
关键词
D O I
10.1016/S0140-6736(99)01122-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice. Methods We analysed prospective data from the Swiss HIV Cohort Study on suppression of viral load and progression to AIDS or death in 2674 outpatients (median age 36 years, 27.3% women) who started HAART in 1995-98. Viral rebound was defined as two consecutive HIV-1-RNA measurements of more than 400 copies/mL. We analysed separately outcomes in patients with a history of antiretroviral treatment and in treatment-naive patients. Findings An estimated 90.7% of treatment-naive patients reached undetectable viral load (<400 copies/mL) by 12 months. Among pretreated patients, estimates ranged from 70.3% treated with one new drug to 78.7% on three new drugs. 2 years after reaching undetectable concentrations, an estimated 20.1% of treatment-naive patients and 35.7-40.1% of pretreated patients had viral rebound. At 30 months, an estimated 6.6% (95% CI 4.6-8.6) of patients who had maintained undetectable concentrations, 9.0% (5.5-12.5) who had viral rebound, and 20.1% (15.3-24.9) who had never reached undetectable concentrations developed AIDS or died. Compared with patients who maintained undetectable viral load, the adjusted relative hazard of AIDS or death was 1.00 (0.66-1.55) for patients with viral rebound, and 2.40 (1.72-3.33) for patients who failed to reach undetectable concentrations. Interpretation The rate of virological failure of HAART was high among these patients, but the probability of clinical progression was low even in patients with viral rebound.
引用
收藏
页码:863 / 868
页数:6
相关论文
共 28 条
[1]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[2]  
BABIKER A, 1997, 6 EUR C CLIN ASP TRE, P207
[3]   Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy [J].
Brodt, HR ;
Kamps, BS ;
Gute, P ;
Knupp, B ;
Staszewski, S ;
Helm, EB .
AIDS, 1997, 11 (14) :1731-1738
[4]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[5]   Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance [J].
Carr, A ;
Samaras, K ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1998, 351 (9119) :1881-1883
[6]   Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients [J].
Casado, JL ;
Perez-Elías, MJ ;
Antela, A ;
Sabido, R ;
Martí-Belda, P ;
Dronda, F ;
Blazquez, J ;
Quereda, C .
AIDS, 1998, 12 (11) :F131-F135
[7]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[8]   Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients [J].
Fatkenheuer, G ;
Theisen, A ;
Rockstroh, J ;
Grabow, T ;
Wicke, C ;
Becker, K ;
Wieland, U ;
Pfister, H ;
Reiser, M ;
Hegener, P ;
Franzen, C ;
Schwenk, A ;
Salzberger, B .
AIDS, 1997, 11 (14) :F113-F116
[9]   THE ROLE OF OBSERVATIONAL STUDIES IN THE EVALUATION OF THERAPY [J].
FEINSTEIN, A .
STATISTICS IN MEDICINE, 1984, 3 (04) :341-345
[10]   SURROGATE AND AUXILIARY END-POINTS IN CLINICAL-TRIALS, WITH POTENTIAL APPLICATIONS IN CANCER AND AIDS RESEARCH [J].
FLEMING, TR ;
PRENTICE, RL ;
PEPE, MS ;
GLIDDEN, D .
STATISTICS IN MEDICINE, 1994, 13 (09) :955-968